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oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to
receiving cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Base-
line risk stratification proformas are presented for oncology patients prior to receiving the following
cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as trastuzumab, vascular
endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for
chronic myeloid leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and
immunomodulatory drugs), RAF and MEK inhibitors or androgen deprivation therapies. Applying these
risk stratification proformas will allow clinicians to stratify cancer patients into low, medium, high and
very high risk of cardiovascular complications prior to starting treatment, with the aim of improving
personalised approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
DOI: https://doi.org/10.1002/ejhf.1920






The following work is licensed under a Creative Commons: Attribution-NonCommercial 4.0 International
(CC BY-NC 4.0) License.
Originally published at:
Lyon, Alexander R; Dent, Susan; Stanway, Susannah; Earl, Helena; et al; Ruschitzka, Frank (2020).
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer thera-
pies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the
Heart Failure Association of the European Society of Cardiology in collaboration with the International
Cardio-Oncology Society. European Journal of Heart Failure, 22(11):1945-1960.
DOI: https://doi.org/10.1002/ejhf.1920
European Journal of Heart Failure (2020) 22, 1945–1960 POSITION PAPER
doi:10.1002/ejhf.1920
Baseline cardiovascular risk assessment in
cancer patients scheduled to receive
cardiotoxic cancer therapies: a position
statement and new risk assessment tools from
the Cardio-Oncology Study Group of the
Heart Failure Association of the European
Society of Cardiology in collaboration with the
International Cardio-Oncology Society
Alexander R. Lyon1*, Susan Dent2, Susannah Stanway3, Helena Earl4,
Christine Brezden-Masley5, Alain Cohen-Solal6, Carlo G. Tocchetti7,
Javid J. Moslehi8, John D. Groarke9, Jutta Bergler-Klein10, Vincent Khoo11,12,
Li Ling Tan13, Markus S. Anker14, Stephan von Haehling15,16, Christoph Maack17,
Radek Pudil18, Ana Barac19, Paaladinesh Thavendiranathan20, Bonnie Ky21,
Tomas G. Neilan22, Yury Belenkov23, Stuart D. Rosen1, Zaza Iakobishvili24,
Aaron L. Sverdlov25, Ludhmila A. Hajjar26, Ariane V.S. Macedo27,
Charlotte Manisty28, Fortunato Ciardiello29, Dimitrios Farmakis30,31,
Rudolf A. de Boer32, Hadi Skouri33, Thomas M. Suter34, Daniela Cardinale35,
Ronald M. Witteles36, Michael G. Fradley21, Joerg Herrmann37, Robert F. Cornell38,
Ashutosh Wechelaker39, Michael J. Mauro40, Dragana Milojkovic41,
Hugues de Lavallade42, Frank Ruschitzka43, Andrew J.S. Coats44,45,
Petar M. Seferovic46, Ovidiu Chioncel47,48, Thomas Thum49, Johann Bauersachs50,
M. Sol Andres1, David J. Wright51, Teresa López-Fernández52, Chris Plummer53,
and Daniel Lenihan54
1Cardio-Oncology Service, Royal Brompton Hospital and Imperial College, London, UK; 2Duke Cancer Institute, Duke University, Durham, NC, USA; 3Breast Unit, Royal
Marsden Hospital, Surrey, UK; 4Department of Oncology, University of Cambridge and NIHR Cambridge Biomedical Research Centre, Cambridge, UK; 5Division of Medical
Oncology, Sinai Health System, Mount Sinai Hospital, Toronto, Canada; 6UMR-S 942, Paris University, Cardiology Department, Lariboisiere Hospital, AP-HP, Paris, France;
7Department of Translational Medical Sciences and Interdepartmental Center for Clinical and Translational Research (CIRCET), Federico II University, Naples, Italy;
8Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA; 9Cardio-Oncology Program, Brigham & Women’s Hospital,
Harvard Medical School, Boston, MA, USA; 10Department of Cardiology, Medical University of Vienna, Vienna, Austria; 11Department of Clinical Oncology, Royal Marsden
Hospital and Institute of Cancer Research, London, UK; 12Department of Medical Imaging and Radiation Sciences, Monash University and Department of Medicine, Melbourne
University, Melbourne, Australia; 13Department of Cardiology, National University Heart Centre, Singapore, National University Health System, Singapore, Singapore; 14Division
of Cardiology and Metabolism, Department of Cardiology, Charité and Berlin Institute of Health Center for Regenerative Therapies (BCRT) and DZHK (German Centre for
Cardiovascular Research), partner site Berlin and Department of Cardiology, Charité Campus Benjamin Franklin, Berlin, Germany; 15Department of Cardiology and Pneumology,
University of Goettingen Medical Center, Goettingen, Germany; 16German Center for Cardiovascular Research (DZHK), partner site Goettingen, Goettingen, Germany;
*Corresponding author. Cardio-Oncology Service, Royal Brompton Hospital, Sydney Street, London SW3 6NP, UK. Tel: +44 20 7352 8121, Email: a.lyon@ic.ac.uk
.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and
reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
1946 A.R. Lyon et al.
17Comprehensive Heart Failure Center, University Clinic Würzburg, Würzburg, Germany; 18First Department of Medicine – Cardioangiology, Charles University Prague, Medical
Faculty and University Hospital Hradec Kralove, Prague, Czech Republic; 19MedStar Heart and Vascular Institute, Georgetown University, Washington, DC, USA; 20Ted Rogers
Program in Cardiotoxicity Prevention and Joint Division of Medical Imaging, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, University of
Toronto, Toronto, Canada; 21University of Pennsylvania, Philadelphia, PA, USA; 22Cardio-Oncology Program, Division of Cardiology, Department of Medicine, Massachusetts
General Hospital, Harvard Medical School, Boston, MA, USA; 23Sechenov Medical University, Moscow, Russia; 24Department of Community Cardiology, Tel Aviv Jaffa District,
Clalit Health Fund and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 25School of Medicine and Public Health, University of Newcastle and “Cancer and the
Heart” Program, Hunter New England LHD, Newcastle, Australia; 26Cardio-Oncology, Department of Cardio-Pneumology, University of São Paulo, São Paulo, Brazil; 27Santa
Cardio-Oncology, Santa Casa de São Paulo and Rede Dor São Luiz, São Paulo, Brazil; 28Barts Heart Centre and University College London, London, UK; 29Department of
Precision Medicine, Luigi Vanvitelli University of Campania, Naples, Italy; 30University of Cyprus Medical School, Nicosia, Cyprus; 31Cardio-Oncology Clinic, Heart Failure Unit,
“Attikon” University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece; 32Department of Cardiology, University of Groningen, University
Medical Center Groningen, Groningen, The Netherlands; 33Cardiology Division, Internal Medicine Department, American University of Beirut Medical Center, Beirut, Lebanon;
34Department of Cardiology, Bern University Hospital, Inselspital, University of Bern, Bern, Switzerland; 35Cardioncology Unit, European Institute of Oncology, IRCCS, Milan,
Italy; 36Stanford University School of Medicine, Stanford, CA, USA; 37Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA; 38Vanderbilt University Medical
Center, Nashville, TN, USA; 39National Amyloidosis Centre, University College London, London, UK; 40Memorial Sloan Kettering Cancer Center, New York, NY, USA;
41Department of Haematology, Hammersmith Hospital, Imperial College, London, UK; 42Department of Haematological Medicine, King’s College Hospital, London, UK;
43University Heart Center, Department of Cardiology, University Hospital Zurich, Zurich, Switzerland; 44University of Warwick, Warwick, UK; 45Pharmacology, Centre of
Clinical and Experimental Medicine, IRCCS San Raffaele Pisana, Rome, Italy; 46Faculty of Medicine and Serbian Academy of Sciences and Arts, University of Belgrade, Belgrade,
Serbia; 47Emergency Institute for Cardiovascular Diseases ‘Prof. C.C. Iliescu’, Bucharest, Romania; 48University of Medicine Carol Davila, Bucharest, Romania; 49Institute of
Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany; 50Department of Cardiology and Angiology, Hannover Medical School,
Hannover, Germany; 51Liverpool Centre for Cardiovascular Science, Liverpool Heart and Chest Hospital, Liverpool, UK; 52Cardiology Service, Cardio-Oncology Unit, La Paz
University Hospital and IdiPAz Research Institute, Ciber CV, Madrid, Spain; 53Department of Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust and
Newcastle University, Newcastle, UK; and 54Cardio-Oncology Center of Excellence, Washington University in St Louis, St Louis, MO, USA
Received 5 January 2020; revised 13 May 2020; accepted 25 May 2020 ; online publish-ahead-of-print 6 August 2020
This position statement from the Heart Failure Association of the European Society of Cardiology Cardio-Oncology Study Group in
collaboration with the International Cardio-Oncology Society presents practical, easy-to-use and evidence-based risk stratification tools
for oncologists, haemato-oncologists and cardiologists to use in their clinical practice to risk stratify oncology patients prior to receiving
cancer therapies known to cause heart failure or other serious cardiovascular toxicities. Baseline risk stratification proformas are presented
for oncology patients prior to receiving the following cancer therapies: anthracycline chemotherapy, HER2-targeted therapies such as
trastuzumab, vascular endothelial growth factor inhibitors, second and third generation multi-targeted kinase inhibitors for chronic myeloid
leukaemia targeting BCR-ABL, multiple myeloma therapies (proteasome inhibitors and immunomodulatory drugs), RAF and MEK inhibitors
or androgen deprivation therapies. Applying these risk stratification proformas will allow clinicians to stratify cancer patients into low,
medium, high and very high risk of cardiovascular complications prior to starting treatment, with the aim of improving personalised
approaches to minimise the risk of cardiovascular toxicity from cancer therapies.
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Introduction
There is a growing epidemic of cardiovascular disease (CVD)
in cancer patients during and after cancer treatment. Improved
cancer-related survival and the development of more targeted
molecular therapies, in addition to the continued use of anthra-
cycline chemotherapy, have resulted in a significant increase in
both current and previously treated cancer patients presenting
to cardiology services with CVD.1 The frequency of cardiovascu-
lar (CV) problems is higher in cancer patients who are receiv-
ing or who have previously received cancer treatments with a
known CV toxicity profile. The average age of oncology patients
is also increasing with the general ageing of the population, which
is in part due to improved survival from CVD. Therefore, there
are a rising number of patients who present to oncology and
haemato-oncology services not only with a new cancer diagnosis
but also with pre-existing CVD or risk factors for CVD.1 This poses
a particular challenge when considering evidence-based oncology































. Current oncology practice, including treatment planning and
protocols for cancer treatments with potentially CV toxicity, pro-
vides unique opportunities to comprehensively assess CV health
before initiation of cancer treatment. This allows cardiologists
and other healthcare professionals, working in partnership with
oncologists and haemato-oncologists, to optimise the manage-
ment of pre-existing CVD and modifiable CV risk factors with
the aim of reducing the risk of CV complications during and
after cancer treatment. The assessment occurring prior to the
initiation of cancer treatment and in patients without overt CVD
or previous cardiotoxicity can be considered a primary prevention
strategy while interventions in patients with pre-existing CVD or
evidence of prior CV toxicity fall into the category of secondary
prevention (Figure 1). Specialist care of CVD in cancer patients
is now offered by dedicated cardio-oncology services which
have emerged over the last 10 years.2,3 This multidisciplinary
approach has the potential not only to reduce morbidity and
mortality from CVD, but also to improve cancer outcomes by
reducing interruptions in cancer treatment due to CV events
and facilitate treatment options with greater potential CV risk.
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Figure 1 Examples of five different patients and primary or secondary prevention based on the history of pre-existing cardiovascular (CV)
disease and/or prior cardiotoxicity from treatment of a previous malignancy.
The aim of a multidisciplinary cardio-oncology approach is to
support best practice, guideline-directed cancer care by main-
taining cancer patients on effective therapies for as long as
recommended, and increase the proportion of cancer patients
who complete their cancer treatment without interruption
for CVD.
Many studies have identified a range of parameters that con-
tribute to CVD risk, but these risk factors are not routinely
and systematically assessed in oncology and haemato-oncology
units at the time of cancer diagnosis or during cancer treatment
(Figure 2). Several guidelines and expert position statements have
been published by professional societies of cardiology, oncology
and cardio-oncology focussed on CVD in cancer patients and all
recommend baseline CV risk assessment in cancer patients prior
to starting potentially cardiotoxic cancer treatments.1,4–6 How-
ever, there is no standardised system or risk assessment tool to
facilitate CV risk stratification in oncology and haemato-oncology
services.
The Cardio-Oncology Study Group from the Heart Fail-
ure Association (HFA) of the European Society of Cardiology
(ESC) hosted a workshop in collaboration with the International
Cardio-Oncology Society (ICOS) dedicated to the development
of ‘Baseline CV risk stratification proformas’ that can be used by
oncology and haemato-oncology teams to stratify cancer patients
for CV risk before initiation of potentially cardiotoxic cancer ther-
apies (Table 1). This position statement summarises the evidence
reviewed at the workshop and subsequently by the co-authors of
this paper, and proposes new HFA-ICOS baseline CV risk stratifi-
cation proformas for seven classes of cancer therapies which are
associated with significant risk of CVD, including but not limited
















































The assessment of baseline CV risk in cancer patients before
starting potentially CV toxic cancer therapies is based on the
following core principles:
• Risk is a continuous variable.
• Multiple CV risk factors may co-exist in an individual cancer
patient and they have an additive or synergistic contribution to
CV risk.
• Evidence or expert consensus exists that a parameter con-
tributes to future risk of CVD and justifies its inclusion in the
baseline CV risk assessment proforma.
• Increased absolute risk (rather than relative risk) is the most
relevant for individual patient-based treatment decisions and
the relative importance attributed to these risk factors.
• Cancer patients identified at increased risk of cancer
treatment-related CV toxicity using these baseline CV risk
assessment proformas should not have their evidence-based
cancer treatment withheld unless they are identified at high or
very high risk and after multidisciplinary discussion between
the treating oncologist/haematologist and cardiologist.
• Baseline CV risk stratification should be completed promptly
and should not delay starting cancer treatment (unless high or
very high risk or pre-existing CVD is present).
• Decisions to withhold effective but potentially cardiotoxic
cancer treatments in cancer patients at high or very high
risk of CVD should only be made after multidisciplinary team
discussion between the treating oncologist/haematologist and
cardiologist balancing treatment efficacy vs. safety and CV risk
for a particular individual.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 The different risk factors which contribute to baseline cardiovascular (CV) risk in a cancer patient scheduled to receive a
cardiotoxic cancer treatment, and a checklist of the clinical history and investigations required at baseline prior to starting a cardiotoxic
cancer therapy. *Cardiac biomarkers (troponin and natriuretic peptides) should be measured where available. BNP, brain natriuretic peptide;
ECG, electrocardiogram; HbA1c, glycated haemoglobin; NT-proBNP, N-terminal pro-brain natriuretic peptide.
• Decisions regarding switching to alternative less cardiotoxic
cancer treatments in cancer patients identified at high or very
high risk of CVD should only be made after multidisciplinary
team discussion between the treating oncologist/haematologist
and cardiologist, balancing treatment efficacy vs. safety and CV
risk for a particular individual.
• The cancer patient should be informed and participate in the
decision making process and be informed of their baseline CV
risk level.
• Cardiovascular treatment interventions should be considered
to mitigate CV risk in cancer patients when identified.
• Pathways of care should exist within an institution using these
proformas so that patients with increased CV risk (medium,
high or very high) have their pre-existing CVD and modifiable
CV risk factors reviewed and optimised by a suitable health-
care professional (e.g. cardio-oncology service, cardiologist or
primary care/family physician) depending on the nature of the
risk, the cardiotoxic treatment planned and healthcare system.
• Baseline CV risk assessment proformas should be easy to
understand and implement in oncology and haemato-oncology
services.
• The application and impact of baseline CV risk assessment
proformas can be assessed using an appropriate clinical audit
and review.
Design and application of baseline
cardiovascular risk proformas
Several cancer drug therapies associated with clinically important
rates of CV toxicity during or after treatment exposure are sum-
















































. therapies are associated with CV risks (e.g. radiation therapy, stem
cell transplantation); however, these are beyond the scope of this
article. There is growing use of immune therapies in oncology, and
there is now considerable evidence of CV toxicities from immune
checkpoint inhibitors (ICIs) and emerging information of HF com-
plicating cytokine release syndrome following chimeric antigen
receptor T (CAR-T) cell therapies for various cancers.7–9 Whilst
no evidence currently exists regarding which clinical, imaging and
laboratory parameters may identify patients at higher risk, given
the severity of these complications we recommend all patients
scheduled to receive ICI or CAR-T therapy have a baseline echocar-
diogram, electrocardiogram (ECG) and measurement of cardiac
troponin and a natriuretic peptide, which serve as a baseline refer-
ence if new cardiac complications develop.
Baseline CV risk assessment proformas have been developed for
seven cardiotoxic cancer therapy classes known to cause a range
of CV toxicities including left ventricular dysfunction (LVD) and
HF (Tables 2–8).10–68 The risk is estimated for all CV complica-
tions from the drug class, e.g. left ventricular dysfunction, QTc
prolongation and arrhythmias, vascular events including myocardial
infarction (MI) and hypertension:
• Anthracycline chemotherapy: the main CV complications of
anthracycline chemotherapy are LVD and HF, and atrial and
ventricular arrhythmias.19,69
• HER2 targeted therapies: the main CV complications of
HER2 targeted therapies are LVD and HF, and systemic
hypertension.44,70,71
• Vascular endothelial growth factor (VEGF) inhibitors [these agents
are also known as angiogenesis inhibitors or VEGF tyrosine kinase
inhibitors (TKIs) as many act via multi-targeted inhibition of tyrosine
kinases]: the main CV complications of VEGF inhibitors are
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Cancer therapy classes identified for cardiovascular baseline risk assessment and associated cardiovascular
toxicity
Cancer treatment class Cancer indication Treatment-related CV toxicity
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Anthracycline chemotherapy
(doxorubicin, epirubicin, daunorubicin, idarubicin)




Atrial and ventricular arrhythmias
HER2-targeted therapies
(trastuzumab, pertuzumab, trastuzumab








TKIs (sunitinib, pazopanib, sorafenib, axitinib,
tivozanib, cabozantinib, regorafenib, lenvatinib,
vandetinib) and antibodies (bevacizumab,
ramucirumab)
VEGF TKIs: renal cancer, hepatocellular
cancer, thyroid cancer, colon cancer,
sarcoma, GIST







Myocardial ischaemia and infarction
QTc prolongation
Multi-targeted kinase inhibitors:
second and third generation BCR-ABL
TKIs
(ponatinib, nilotinib, dasatinib, bosutinib)
Chronic myeloid leukaemia Arterial thrombosis
(myocardial infarction, stroke and PAODa)
Venous thromboembolism
Hypertension








Multiple myeloma Heart failured
Asymptomatic LVSDd
Myocardial ischaemia and infarction





















anti-programmed cell death 1 inhibitors
(nivolumab, pembrolizumab)
anti-cytotoxic T-lymphocyte-associated
protein 4 inhibitor (ipilimumab)
anti-programmed death-ligand 1 inhibitors
(avelumab, atezolizumab, durvalumab)
Melanoma (metastatic and adjuvant)
Metastatic renal cancer, non-small cell
lung cancer, small cell lung cancer,
refractory Hodgkin’s lymphoma,
metastatic triple negative breast
cancer, metastatic urothelial cancer,
liver cancer, MMR-deficient cancer





Acute coronary syndromes including
atherosclerotic plaque rupture and vasculitis
AV, atrio-ventricular; CV, cardiovascular; ER, oestrogen receptor; GIST, gastro-intestinal stromal tumour; GnRH, gonadotropin release hormone; LVSD, left ventricular systolic
dysfunction; MMR, mismatch repair; PAOD, peripheral arterial occlusive disease; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor.
aAssociated with ponatinib.
bAssociated with ponatinib and nilotinib.
cAssociated with dasatinib.
dAssociated with carfilzomib.
eAssociated with vemurafenib and cobimetinib.
fThe risk scores for androgen deprivation therapies in this position statement relate to androgen deprivation therapies for prostate cancer only.
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Table 2 Baseline cardiovascular risk stratification proforma for anthracycline chemotherapy
Risk factor Score Level of
evidence
References
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Previous cardiovascular disease
Heart failure or cardiomyopathy Very high B 10,11
Severe valvular heart disease High C 11
Myocardial infarction or previous coronary revascularisation (PCI or CABG) High C 10–12
Stable angina High C 10–12
Baseline LVEF <50% High B 10
Borderline LVEF 50–54% Medium2 C
Cardiac biomarkers (where available)
Elevated baseline troponina Medium1 C 13–15
Elevated baseline BNP or NT-proBNPa Medium1 C 16,17
Demographic and cardiovascular risk factors
Age ≥80 years High B 10,12,18
Age 65–79 years Medium2 B 10,18–20
Hypertensionb Medium1 B 11,12,21
Diabetes mellitusc Medium1 C 10–12
Chronic kidney diseased Medium1 C
Previous cardiotoxic cancer treatment
Previous anthracycline exposure High B 18–20,22–25
Prior radiotherapy to left chest or mediastinum High C 20,22,23,26,27
Previous non-anthracycline-based chemotherapy Medium1 C 24,25,28
Lifestyle risk factors
Current smoker or significant smoking history Medium1 C 23
Obesity (BMI>30 kg/m2) Medium1 C 20,29,30
Risk level
BMI, body mass index; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic
peptide; PCI, percutaneous coronary intervention.
Low risk = no risk factor OR one medium1 risk factor; Medium risk = medium risk factors with a total of 2–4 points; High risk = medium risk factors with a total of ≥5
points OR any high risk factor; Very high risk = any very high risk factor.
aElevated above the upper limit of normal for local laboratory reference range.
bSystolic blood pressure >140mmHg or diastolic blood pressure >90mmHg, or on treatment.
cGlycated haemoglobin >7.0% or >53mmol/mol, or on treatment.
dEstimated glomerular filtration rate <60mL/min/1.73m2 .
Please see online supplementary Table S2 for the 1 page printable version for clinical use.
systemic hypertension, LVD and HF, QTc prolongation and
arterial thrombosis including MI.48,53,57,72
• Multi-targeted kinase inhibitors for chronic myeloid leukaemia (CML)
targeting BCR-ABL (often called BCR-ABL TKIs): the main CV
complications of multi-targeted kinase inhibitors for CML
targeting BCR-ABL include arterial thrombosis leading to
MI, stroke and peripheral arterial occlusive disease (pona-
tinib), venous thromboembolism, systemic hypertension, LVD
and HF, accelerated atherosclerosis (ponatinib and nilotinib),
QTc prolongation (nilotinib) and pulmonary hypertension
(dasatinib).59,62,73–78
• Proteasome inhibitors (PIs) and immunomodulatory drugs (IMIDs):
the main CV complications of PIs and IMIDs in combina-
tion are LVD and HF, ischaemia and MI, atrial and ven-
tricular arrhythmias, venous thromboembolism and arterial
thrombosis.66,67,79
• Combination RAF and MEK inhibitor treatment: the main CV com-




























.. hypertension for all combinations and QTc prolongation for
one combination (vemurafenib and cobimetinib).80,81
• Androgen deprivation therapies (ADT) for prostate cancer treatment
including gonadotropin release hormone (GnRH) agonists: ADT
are associated with an increased risk of diabetes mellitus,
hypertension and atherosclerosis (see below).82–84
• Immune checkpoint inhibitors: myocarditis including fulminant
myocarditis, non-inflammatory HF, ventricular arrhythmias,
atrio-ventricular block, sudden cardiac death, acute coronary
syndromes including atherosclerotic plaque rupture and vas-
culitis.
The first six proformas each comprise of a single table with five
columns on one page. This can be printed or accessed electroni-
cally, completed by the appropriate oncology or haemato-oncology
healthcare professional with the patient, and filed in the patient’s
medical records (paper or digital):
• Column 1 lists the CV risk factors
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 3 Baseline cardiovascular risk stratification proforma for HER2-targeted cancer therapies (trastuzumab,
pertuzumab, T-DM1, lapatinib, neratinib)
Risk factor Score Level of
evidence
References
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Previous cardiovascular disease
Heart failure or cardiomyopathy Very high C 31
Myocardial infarction or CABG High B 31,32
Stable angina High B 31–34
Severe valvular heart disease High C 31
Baseline LVEF <50% High C
Borderline LVEF 50–54% Medium2 B 35–37
Arrhythmiaa Medium2 C 31,32
Cardiac biomarkers (where available)
Elevated baseline troponinb Medium2 B 38,39
Elevated baseline BNP or NT-proBNPb Medium2 C 17
Demographic and cardiovascular risk factors
Age ≥80 years High B 32,33
Age 65–79 years Medium2 B 35,36,40,41
Hypertensionc Medium1 B 32–36,42,43
Diabetes mellitusd Medium1 C 31,32,42
Chronic kidney diseasee Medium1 C 32
Current cancer treatment regimen
Includes anthracycline before HER2-targeted therapy Medium1 f B 32,40,41,43–45
Previous cardiotoxic cancer treatment
Prior trastuzumab cardiotoxicity Very high C
Prior (remote) anthracycline exposureg Medium2 B 42
Prior radiotherapy to left chest or mediastinum Medium2 C 41,46,47
Lifestyle risk factors
Current smoker or significant smoking history Medium1 C 34
Obesity (BMI>30 kg/m2) Medium1 C 29,34,43,45
Risk level
BMI, body mass index; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic
peptide.
Low risk = no risk factor OR one medium1 risk factor; Medium risk = medium risk factors with a total of 2–4 points; High risk = medium risk factors with a total of ≥5
points OR any high risk factor; Very high risk = any very high risk factor.
aAtrial fibrillation, atrial flutter, ventricular tachycardia, or ventricular fibrillation.
bElevated above the upper limit of normal for local laboratory reference range.
cSystolic blood pressure >140mmHg or diastolic blood pressure >90mmHg, or on treatment.
dGlycated haemoglobin >7.0% or >53mmol/mol, or on treatment.
eEstimated glomerular filtration rate <60mL/min/1.73m2 .
fHigh risk if anthracycline chemotherapy and trastuzumab delivered concurrently.
gPrevious malignancy (not current treatment protocol).
Please see online supplementary Table S3 for the 1 page printable version for clinical use.
• Column 2 is the box to complete if present (yes/no)
• Column 3 is the weighting of the risk factor (medium, high or
very high)
• Column 4 has the level of evidence (LoE) supporting the
inclusion and weighting based on the standard LoE definitions
used in professional cardiology and oncology guidelines; and
• Column 5 has references for the publications providing evi-
dence for the risk factor having predictive value pre-treatment
for future CV adverse events which supports inclusion and level
of risk weighting.
The conceptual background of these recommendations is that



















.. the CV risk.1,85 The clinical and demographic variables contributing
to increased CV risk can be divided into risk factor classes which
are similar for the six cancer-related treatments associated with
CVD and HF in particular. The CV risk factor classes included in
the first six proformas are:
• Pre-existing CVD
• Elevated circulating cardiac biomarkers pre-treatment (if mea-
sured)
• Demographic and co-existing medical conditions recognised as
CV risk factors
• Previous cardiotoxic cancer treatment
• Lifestyle-related CV risk factors.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 4 Baseline cardiovascular risk stratification proforma for vascular endothelial growth factor inhibitors
Risk factor Score Level of
evidence
References
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Previous cardiovascular disease
Heart failure or cardiomyopathy Very high C 48–50
Arterial vascular disease (IHD, PCI, CABG, stable angina, TIA, stroke, PVD) Very high C 50–52
Venous thrombosis (DVT or PE) High C
Baseline LVEF <50% High C
Borderline LVEF 50–54% Medium2 C
QTc ≥480ms High C
450ms ≤ QTc <480ms (men) 460ms ≤ QTc <480ms (women) Medium2 C
Arrhythmiaa Medium2 C 50
Cardiac biomarkers (where available)
Elevated baseline troponinb Medium1 C 50
Elevated baseline BNP or NT-proBNPb Medium1 C 53
Demographic and cardiovascular risk factors
Age ≥75 years High C 54–56
Age 65–74 years Medium1 C 48,54,56
Hypertensionc High C 48,50–52,54,55
Diabetes mellitusd Medium1 C 50
Hyperlipidaemiae Medium1 C 49,50
Chronic kidney diseasef Medium1 C 57
Proteinuria Medium1 C
Previous cardiotoxic cancer treatment
Prior anthracycline exposure High C
Prior radiotherapy to left chest or mediastinum Medium1 C
Lifestyle risk factors
Current smoker or significant smoking history Medium1 C 50
Obesity (BMI>30 kg/m2) Medium1 C 50,54,58
Risk level
BMI, body mass index; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; DVT, deep vein thrombosis; IHD, ischaemic heart disease; LVEF, left ventricular
ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; PCI, percutaneous coronary intervention; PE, pulmonary embolism; PVD, peripheral vascular disease;
TIA, transient ischaemic attack.
Low risk = no risk factor OR one medium1 risk factor; Medium risk = medium risk factors with a total of 2–4 points; High risk = medium risk factors with a total of ≥5
points OR any high risk factor; Very high risk = any very high risk factor.
aAtrial fibrillation, atrial flutter, ventricular tachycardia, or ventricular fibrillation.
bElevated above the upper limit of normal for local laboratory reference range.
cSystolic blood pressure >140mmHg or diastolic blood pressure >90mmHg, or on treatment.
dGlycated haemoglobin >7.0% or >53mmol/mol, or on treatment.
eNon-high-density lipoprotein cholesterol level >3.8mmol/L (>145mg/dL).
fEstimated glomerular filtration rate <60mL/min/1.73m2 .
Please see online supplementary Table S4 for the 1 page printable version for clinical use.
Each risk factor class includes a range of risk factors or variables
identified as contributing to CV risk for patients receiving the
specific cancer therapy according to the evidence available and
expert opinion.
Once completed, a risk level can be calculated from the summary
using the following simple rules:
1 Patients with no risk factors are ‘low risk’
2 Patients with one or more risk factors are categorised accord-
ing to the highest risk factor present:
• Patients with one or more very high risk factors—their
risk level is ‘very high’






















.. 3 Medium risk factors are given a point weighting as medium1 or
medium2
• Patients with one medium1 risk factor only are ‘low risk’
• Patients with a single medium2 risk factor or more than one
medium1 risk factor with points totalling 2–4 are ‘medium
risk’
• Patients with several medium risk factors with points
totalling 5 or more points are ‘high risk’
Evidence for defining the absolute risk is limited or absent for
each risk factor for every drug class. Based on discussion and
expert opinion, the risk of future cardiotoxicity for each of the
risk groups can be considered as follows: low risk <2%, medium
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 5 Baseline cardiovascular risk stratification proforma for multi-targeted kinase inhibitors for chronic myeloid
leukaemia including second and third generation BCR-ABL tyrosine kinase inhibitors
Risk factor Score Level of
evidence
References
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Previous cardiovascular disease
Arterial vascular disease (IHD, PCI, CABG, stable angina, TIA, stroke, PVD) Very high C 59,60
Arterial thrombosis with TKI Very high C
Heart failure or LVSD High C
BCR-ABL TKI-mediated LVSD High C
Abnormal ABPIf High C
Pulmonary arterial hypertensiong High C
Baseline LVEF <50% High C
Venous thromboembolism (DVT/PE) Medium2 C 60,61
Arrhythmiaa Medium2 C
QTc ≥ 480ms High C
450ms ≤ QTc < 480ms (men) 460ms ≤ QTc < 480ms (women) Medium2 C
Demographic and other cardiovascular risk factors
Cardiovascular disease 10-year risk score >20% High B 62
Hypertensionb Medium2 B 59–61
Diabetesc Medium1 B 63
Hyperlipidaemiad Medium1 B 60,61
Age ≥75 years High C
Age 65–74 years Medium2 B 61
Age ≥60 years Medium1 B 61
Chronic kidney diseasee Medium1 C
Family history of thrombophilia Medium1 C
Lifestyle and other factors
Current smoker or significant smoking history High B 60
Obesity (BMI>30 kg/m2) Medium1 C
Risk level
ABPI, ankle–brachial pressure index; BMI, body mass index; CABG, coronary artery bypass graft; DVT, deep vein thrombosis; IHD, ischaemic heart disease; LVEF, left ventricular
ejection fraction; LVSD, left ventricular systolic dysfunction; PCI, percutaneous coronary intervention; PCI, percutaneous coronary intervention; PE, pulmonary embolism;
PVD, peripheral vascular disease; TIA, transient ischaemic attack; TKI, tyrosine kinase inhibitor.
Low risk = no risk factor OR one medium1 risk factor; Medium risk = medium risk factors with a total of 2–4 points; High risk = medium risk factors with a total of ≥5
points OR any high risk factor; Very high risk = any very high risk factor.
aAtrial fibrillation, atrial flutter, ventricular tachycardia, or ventricular fibrillation.
bSystolic blood pressure >140mmHg or diastolic blood pressure >90mmHg, or on treatment.
cGlycated haemoglobin >7.0% or >53mmol/mol, or on treatment.
dNon-high-density lipoprotein cholesterol level >3.8mmol/L (>145mg/dL).
eEstimated glomerular filtration rate <60mL/min/1.73m2 .
fABPI ≤0.9.
gPeak systolic pulmonary artery pressure at rest ≥35mmHg when estimated non-invasively on echocardiography.
Please see online supplementary Table S5 for the 1 page printable version for clinical use.
risk 2–9%, high risk 10–19%, very high risk ≥20%. These should
be considered a guide and future studies are needed to validate and
refine these ranges and risk weighting.
The seventh baseline CV risk assessment proforma relates
to ADT including GnRH agonists and other anti-androgens (e.g.
17𝛼-hydroxylase inhibitors) used for prostate cancer. The risks
relate to the development of atherosclerotic vascular disease, and
there are several established CV risk calculators for MI and stroke
associated with atherosclerosis (Table 9 and ADT baseline CV
risk assessment proformas).86–88 The risk categories are different
from those for the other oncology drugs as they are based on the
10-year risk of events. Several studies have shown that, particularly
for prostate cancer patients who have a mean age >60 years and




















.. agonists given as ADT increase CV risk and mortality, and preven-
tative strategies are needed.89 Whilst these CV risk calculators
were not specifically developed for cancer patients receiving
GnRH agonists or other ADT, and frequently excluded patients
with active cancer, they are established from large population
studies and included in the ESC guidelines for CVD prevention and
are also included in many national cardiology society guidelines.
The risk calculators collect various parameters associated with
future risk of atherosclerosis-related CVD, although the specific
parameters required vary between the different risk calculators
(online supplementary Table S1). It was the consensus of the
authors to recommend the use of these established CV risk
calculators specifically for patients receiving ADT including GnRH
agonists for prostate cancer which have an increased risk of MI
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 6 Baseline cardiovascular risk stratification proforma for proteasome inhibitors and immunomodulatory
agents for multiple myeloma
Risk factor Score Level of
evidence
References
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Previous cardiovascular disease
Heart failure or cardiomyopathy Very high C 64
Prior proteasome inhibitor cardiotoxicity Very high C
Venous thrombosis (DVT or PE) Very high C 64
Cardiac amyloidosis Very high C
Arterial vascular disease (IHD, PCI, CABG, stable angina, TIA, stroke, PVD) Very high C 64
Prior immunomodulatory drug CV toxicity High B 65
Baseline LVEF <50% High C
Borderline LVEF 50–54% Medium2 C
Arrhythmiaa Medium2 C 64
Left ventricular hypertrophyb Medium1 C
Cardiac biomarkers (where available)
Elevated baseline troponinc Medium2 C
Elevated baseline BNP or NT-proBNPc High B 66
Demographic and cardiovascular risk factors
Age ≥75 years High C
Age 65–74 years Medium1 C
Hypertensiond Medium1 C 64,67
Diabetes mellituse Medium1 C
Hyperlipidaemiaf Medium1 C 64
Chronic kidney diseaseg Medium1 C
Family history of thrombophilia Medium1 C
Previous cardiotoxic cancer treatment
Prior anthracycline exposure High C 68
Prior thoracic spine radiotherapy Medium1 C 68
Current myeloma treatment
High-dose dexamethasone >160mg/month Medium1 C
Lifestyle risk factors
Current smoker or significant smoking history Medium1 C 67
Obesity (BMI>30 kg/m2) Medium1 C
Risk level
BMI, body mass index; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; DVT, deep vein thrombosis; IHD, Ischaemic heart disease; LVEF, left ventricular
ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; PCI, percutaneous coronary intervention; PE, pulmonary embolism; PVD, peripheral vascular disease;
TIA, transient ischaemic attack.
Low risk = no risk factor OR one medium1 risk factor; Medium risk = medium risk factors with a total of 2–4 points; High risk = medium risk factors with a total of ≥5
points OR any high risk factor; Very high risk = any very high risk factor.
aAtrial fibrillation, atrial flutter, ventricular tachycardia, or ventricular fibrillation.
bLeft ventricular wall thickness >1.2 cm.
cElevated above the upper limit of normal for local laboratory reference range.
dSystolic blood pressure >140mmHg or diastolic blood pressure >90mmHg, or on treatment.
eGlycated haemoglobin >7.0% or >53mmol/mol or on treatment.
fNon-high-density liporotein cholesterol level >3.8mmol/L (>145mg/dL).
gEstimated glomerular filtration rate <60mL/min/1.73m2 .
Please see online supplementary Table S6 for the 1 page printable version for clinical use.
and stroke. The coronary heart disease risk level can then be
calculated using the online web-based calculator for the risk score
as follows:
• <10% 10-year risk = low risk level
• 10–19% 10-year risk = medium risk level
• ≥20% 10-year risk = high risk level
The result should be communicated to the patient and to















. cardiologist, cardio-oncologist) to address modifiable CV risk
factors according to ESC guidelines for CVD prevention.86 These
are primary prevention CV risk calculators and are only suitable
for cancer patients scheduled to receive ADT who have not
previously presented with the clinical manifestations of atheroscle-
rotic disease. Any prostate cancer patient with a previous history
of CVD is high risk and should be evaluated by an appropriate
healthcare professional to review their symptom status and CV
risk factor control. These CV risk calculators are not suitable for
other cardiotoxic cancer therapies where there is an increased
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Table 7 Baseline cardiovascular risk stratification proforma for combination RAF and MEK inhibitors
(dabrafenib+ trametinib, vemurafenib+ cobimetinib, encorafenib+binimetinib)
Risk factor Score Level of
evidence
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Previous cardiovascular disease
Heart failure or cardiomyopathy Very high C
Myocardial infarction or CABG High C
Stable angina High C
Severe valvular heart disease High C
Borderline LVEF 50–54% Medium2 C
Arrhythmiaa Medium1 C
Cardiac biomarkers (where available)
Elevated baseline troponinb Medium2 C
Elevated baseline BNP or NT-proBNPb Medium2 C
Demographic and cardiovascular risk factors
Age ≥65 years Medium1 C
Hypertensionc Medium2 C
Diabetes mellitusd Medium1 C
Chronic kidney diseasee Medium1 C
Previous cardiotoxic cancer treatment
Prior anthracycline exposuref High C
Prior radiotherapy to left chest or mediastinum Medium2 C
Lifestyle risk factors
Current smoker or significant smoking history Medium1 C
Obesity (BMI>30 kg/m2) Medium1 C
Risk level
BMI, body mass index; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic
peptide.
Low risk = no risk factor OR one medium1 risk factor; Medium risk = medium risk factors with a total of 2–4 points; High risk = medium risk factors with a total of ≥5
points OR any high risk factor; Very high risk = any very high risk factor.
aAtrial fibrillation, atrial flutter, ventricular tachycardia, or ventricular fibrillation.
bElevated above the upper limit of normal for local laboratory reference range.
cSystolic blood pressure >140mmHg or diastolic blood pressure >90mmHg, or on treatment.
dGlycated haemoglobin >7.0% or >53mmol/mol, or on treatment.
eEstimated glomerular filtration rate <60mL/min/1.73m2 .
fPrevious malignancy.
Please see online supplementary Table S7 for the 1 page printable version for clinical use.
risk of HF, hypertension, QT prolongation and other CVDs. In
addition, data on the increased CV risk in women receiving GnRH
agonists for breast or ovarian cancer are lacking and therefore this
proforma is currently only applicable to men with prostate cancer
scheduled to receive a GnRH agonist.
We recommend completion of the baseline CV risk assess-
ment proformas in all patients scheduled to receive one of the
seven oncology drug classes with potential cardiotoxicity listed in
Table 1. This can be performed after the decision has been made
by the treating oncologist or haematologist to start a potentially
cardiotoxic cancer treatment. It is important to emphasise that
this needs to be completed promptly so that cancer treatment
is not delayed and can be commenced safely. In emergency sce-
narios, guideline-based cancer treatment should be commenced
and the baseline CV risk assessment proformas can be completed
once clinical stability has been achieved (e.g. CML presenting



























.. Following completion of the baseline CV risk assessment
proformas the risk level should be recorded in the patient’s
medical records, reviewed by the treating oncologist or
haemato-oncologist and communicated to the patient and their
primary care physician. The specific treatment pathways for each
of the drug categories and risk levels is beyond the scope of this
position statement and will be addressed in a future HFA position
statement, but the authors recommend, conceptually, the following
general principles until more detailed guidance is available:
• Low risk level cancer patients continue with treatment with
CV surveillance as appropriate according to local, national and
international guidelines.
• Medium risk cancer patients require closer monitoring of CV
health during treatment or consideration for referral for a
cardio-oncology or cardiology assessment.
• High and very high risk level patients are referred for a
cardio-oncology or cardiology assessment, ideally in a specialist
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Table 8 Baseline cardiovascular risk stratification
proforma for androgen deprivation therapies
including gonadotrophin-releasing hormone agonists
(goserelin, leuprolide) and anti-androgen therapies
(abiraterone) for prostate cancer
Clinical risk scorea Score
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Known pre-existing cardiovascular
disease (CVD)b or CVD 10-year risk
score ≥20%
High
CVD 10-year risk score ≥10% to <20% Medium
CVD 10-year risk score <10% Low
CVD, cardiovascular disease.
Risk factors and variables required: age, gender, ethnic group, height, weight,
social class indicator (Townsend quintile), smoking status (current, ex- or
non-smoker), total cholesterol, high-density lipoprotein cholesterol, systolic
blood pressure (mmHg), diabetes status (yes/no), family history of premature
CVD (before 60 years) (yes/no), chronic kidney disease (yes/no), atrial fibrillation
(yes/no), systemic inflammatory disease (e.g. rheumatoid arthritis, psoriasis)
(yes/no).
aFor validated CVD risk scores, see Table 9.
bPrior symptomatic coronary artery disease, carotid artery disease or peripheral
artery disease, e.g. stable angina, acute myocardial infarction, transient ischaemic
attack/stroke, ischaemic claudication.
Table 9 Atherosclerosis-related cardiovascular risk
calculators
Risk score Website
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ESC HeartScore www.heartscore.org
QRISK®3 https://qrisk.org/three
JBS3 risk score (2014) http://www.jbs3risk.com
ACC/AHA pooled cohort
CV risk calculator (2013)
http://www.cvriskcalculator.com
ACC, American College of Cardiology; AHA, American Heart Association; ESC,
European Society of Cardiology; JBS, Joint British Societies.
cardio-oncology service (if available) to optimise management
of their pre-existing CVD and modifiable CV risk factors, and
provide a personalised management plan for surveillance during
cancer treatment.
It is important that pathways exist to minimise the time delay
from risk assessment and referral to cardiology clinical assessment,
and the decision and management plan are communicated to the
referring oncology or haemato-oncology team promptly to prevent
any delay in starting cancer treatment, following the core principles
of a cardio-oncology service.2 The timing and nature of CV
surveillance recommendations will depend upon various factors
including the cardiotoxicity profile of the cancer therapy required
(Table 1), the risk factors contributing to the risk level calculation
and patient preference. CV imaging and cardiac biomarkers are
available for surveillance and detection of early cardiotoxicity, and



















































































.. therapies and surveillance algorithms are the topic of two HFA
position statements (in preparation).
We recommend that following implementation of these risk
proformas, which could be digital or paper-based depending upon
local medical records, an audit and review of the risk stratification
process is performed to identify the frequency of application,
percentage of risk assessments completed, the actions taken from
the assessment and how that conforms to local pathways and
standards of care. Oncologists and haemato-oncologists should
identify cardiologists with whom to collaborate in setting up
pathways of care for their high risk and very high risk patients.
If cardiology support is not available locally, then whilst identifying
regional or national options these risk proformas should provide
a guide for oncologists to consider alternative, non-cardiotoxic
cancer therapies in patients identified as high risk or very high
risk where alternative treatment options are available. In the long
term collection of outcome data, and comparison to retrospective
datasets regarding CV events, could be considered. We suggest
collaborative studies between centres implementing these risk
stratification proformas to assess their impact in reducing CV
complications of cancer therapies as well as changes in the overall
cancer and CV outcomes. Large datasets can also serve to refine
the weighting of risk for the different parameters for each cancer
drug class, with the ultimate aim to improve the sensitivity and
predictive value.
Conclusions and future directions
Cardiology and oncology professional society guidelines and expert
position statements on CVD in cancer patients uniformly recom-
mend baseline CV risk assessment for oncology patients scheduled
to receive potentially cardiotoxic cancer therapies.1,4–6 Here we
present proformas for baseline CV risk assessment which can be
employed by oncology and haemato-oncology services for patients
scheduled to receive one of seven cardiotoxic cancer therapies.
Assessment of baseline CV risk is part of a personalised approach
to care for cancer patients. The identification of cancer patients
who are at an increased risk of CV complications in a timely
manner is important so that appropriate measures can be imple-
mented to eliminate or at least mitigate their CV risk and ensure,
where possible, that cancer patients receive their treatment safely.
There is the potential for these proformas to be electronic with
semi-automated population of the fields from the electronic patient
record if a suitable platform exists. Future studies are required to
validate and refine these proformas, including the specific weight-
ing of each risk factor and the addition of new risk factors as they
are identified. The impact of proformas upon overall survival and
both CV-related and cancer-related outcomes and mortality needs
to be assessed as well. The long-term goal is to improve both
oncology and CV outcomes for this patient population through
a personalised approach to CV risk, which should allow cancer
patients to complete their evidence-based cancer treatments free
from CV toxicity and CVD, leading to an improvement in overall
survival.
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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